Patents by Inventor Andrea Hanefeld
Andrea Hanefeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220110830Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form using a 3D printing process as well. The process is a printing process that allows the production of solid pharmaceutical administration forms in a flexible manner and in conformity with the high quality standards required for the production of pharmaceuticals.Type: ApplicationFiled: December 22, 2021Publication date: April 14, 2022Applicant: Merck Patent GmbHInventors: Stefan SCHILLER, Andrea HANEFELD, Gerhard JONSCHKER
-
Publication number: 20220040917Abstract: The present invention is directed to a process for the preparation of a coated solid pharmaceutical dosage form using 3D printing technology.Type: ApplicationFiled: September 12, 2019Publication date: February 10, 2022Applicant: MERCK PATENT GMBHInventors: Malte BOGDAHN, Stefan SCHILLER, Andrea HANEFELD, Simon GEISSLER
-
Patent number: 11229577Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form using a 3D printing process as well. The process is a printing process that allows the production of solid pharmaceutical administration forms in a flexible manner and in conformity with the high quality standards required for the production of pharmaceuticals.Type: GrantFiled: September 8, 2017Date of Patent: January 25, 2022Assignee: Merck Patent GmbHInventors: Stefan Schiller, Andrea Hanefeld, Gerhard Jonschker
-
Patent number: 10561622Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).Type: GrantFiled: October 15, 2015Date of Patent: February 18, 2020Assignee: Merck Patent GmbHInventors: Andrea Hanefeld, Markus Weigandt, Stefan Schiller, Marc Schneider, Michael C. Lehr
-
Patent number: 10369217Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.Type: GrantFiled: May 12, 2015Date of Patent: August 6, 2019Assignee: MERCK PATENT GMBHInventors: Andrea Hanefeld, Markus Weigandt, Michael Wolf, Percy Knolle, Matthias Schroeder, Regina Scherliess, Peter Walden, Andrea Diedrich, Hartwig Steckel, Renato Brito Baleeiro
-
Publication number: 20190192383Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form using a 3D printing process as well. The process is a printing process that allows the production of solid pharmaceutical administration forms in a flexible manner and in conformity with the high quality standards required for the production of pharmaceuticals.Type: ApplicationFiled: September 8, 2017Publication date: June 27, 2019Applicant: Merck Patent GmbHInventors: Stefan SCHILLER, Andrea HANEFELD, Gerhard JONSCHKER
-
Patent number: 10111952Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: GrantFiled: October 6, 2017Date of Patent: October 30, 2018Assignee: MERCK PATENT GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Publication number: 20180071386Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: ApplicationFiled: October 6, 2017Publication date: March 15, 2018Applicant: Merck Patent GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Patent number: 9808521Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.Type: GrantFiled: June 30, 2016Date of Patent: November 7, 2017Assignee: MERCK PATENT GMBHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Publication number: 20170312229Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).Type: ApplicationFiled: October 15, 2015Publication date: November 2, 2017Applicant: Merck Patent GmbHInventors: Andrea HANEFELD, Markus WEIGANDT, Stefan SCHILLER, Marc SCHNEIDER, Michael C. LEHR
-
Publication number: 20170143822Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.Type: ApplicationFiled: May 12, 2015Publication date: May 25, 2017Applicant: MERCK PATENT GMBHInventors: Andrea HANEFELD, Markus WEIGANDT, Michael WOLF, Percy KNOLLE, Matthias SCHROEDER, Regina SCHERLIESS, Peter WALDEN, Andrea DIEDRICH, Hartwig STECKEL, Renato Brito BALEEIRO
-
Publication number: 20160303228Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: ApplicationFiled: June 30, 2016Publication date: October 20, 2016Applicant: Merck Patent GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Patent number: 9433673Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.Type: GrantFiled: February 2, 2015Date of Patent: September 6, 2016Assignee: MERCK PATENT GMBHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Publication number: 20150224189Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: ApplicationFiled: February 2, 2015Publication date: August 13, 2015Applicant: MERCK PATENT GMBHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Patent number: 8980324Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.Type: GrantFiled: July 13, 2009Date of Patent: March 17, 2015Assignee: Merck Patent GmbHInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Patent number: 8211948Abstract: The present invention relates to a lyophilized nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilized nanoemulsion by redispersion, and to a process for the preparation of the lyophilized nanoemulsion.Type: GrantFiled: February 26, 2009Date of Patent: July 3, 2012Assignee: Merck Patent GmbHInventors: Andrea Hanefeld, Martina Schmidt, Simon Geissler, Peter Langguth
-
Publication number: 20110123620Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.Type: ApplicationFiled: July 13, 2009Publication date: May 26, 2011Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
-
Publication number: 20110015266Abstract: The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion.Type: ApplicationFiled: February 26, 2009Publication date: January 20, 2011Inventors: Andrea Hanefeld, Martina Schmidt, Simon Geissler, Peter Langguth